Project Grant R21EB033963
Award Date 8/1/23
Completion Date 7/31/26
Dollars Obligated $435K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
- This Project Grant award of $374,199 from the National Center for Advancing Translational Sciences (NCATS), CFDA 93.350, supports the development of an in situ capsid protein and DNA imaging platform to characterize therapeutic adeno-associated virus (AAV) titers. AAV is a leading gene delivery vector for treating human diseases, but safety challenges related to high AAV vector genome titers have resulted in adverse events, including patient deaths. This project aims to create analytical methods...
- This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), is focused on developing a stable production cell line for recombinant adeno-associated virus (rAAV) biomanufacturing. The $436,658 award aims to address key challenges with current transient transfection-based rAAV production methods, such as low productivity, scalability...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $284,331 to the University of Massachusetts Medical School (UMass Medical) to develop novel methods for characterizing the structure and stability of gene therapy vector genomes in human hepatocytes when challenged by natural viral infections. The key objectives are to: 1) Track changes in the abundance and episomal...
- This Project Grant award of $1,640,169 from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) supports Synvivia, Inc.'s development of a platform to identify cyclic peptides that can increase the yield and quality of adeno-associated virus (AAV) vectors for gene therapy manufacturing. The key products and services to be delivered include: Demonstrating that Synvivia's cyclic peptide discovery library contains compounds that...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research provides $704,635 to the University of Florida to develop optimized adeno-associated virus (AAV) vectors for gene therapy of hemophilia. Specifically, the award aims to engineer both capsid- and genome-modified AAV3 vectors that can transduce human hepatocytes more efficiently than current AAV5 vectors, potentially reducing the required vector dose and...
- This Project Grant award of $3,192,404 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research on immunomodulation in adeno-associated virus (AAV) gene therapy. The research aims to better understand, model, and manage immune responses that can arise from systemic dosing of recombinant AAV vectors, which pose a major challenge in the treatment of monogenic disorders using this gene...
- This federal Project Grant award from the National Institutes of Health (NIH) Office of Research Infrastructure Programs (CFDA 93.351) provides $887,626 to the University of Miami to conduct research focused on preventing immune responses towards adeno-associated virus (AAV)-delivered anti-HIV antibodies. The project aims to explore two strategies to induce tolerance and prevent anti-drug antibody (ADA) formation in response to AAV-mediated gene therapy delivering broadly neutralizing HIV...
- This federal Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), is supporting research to develop an efficient synthetic RNA switch that can regulate the timing and dosing of gene therapies delivered via adeno-associated viral (AAV) vectors. The $1,158,262 award to the University of Massachusetts Medical School will fund the...
- This Project Grant award from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), aims to extend the reach and efficacy of adeno-associated virus (AAV)-based gene therapy by utilizing endogenously produced extracellular vesicles (EVs) to transport engineered transgene mRNA or protein products among cells and across tissues. The $860,750 award to Emory University will...
- This federal Project Grant award from the National Eye Institute (NEI), part of the Department of Health and Human Services, provides $719,012 in funding to the University of California, Davis to conduct research on optimizing the delivery of adeno-associated virus (AAV) gene therapies via the suprachoroidal space in non-human primates for the treatment of retinal diseases. The goal is to enhance the biodistribution, cellular tropism, durability, and safety of suprachoroidal AAV administration...